A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention | Zendy

Hitinder S. Gurm | Zendy; Umesh Tamhane | Zendy; Pascal Meier | Zendy; Paul Grossman | Zendy; Stanley Chetcuti | Zendy; Eric Bates | Zendy

Open Access

A Comparison of Abciximab and Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Primary Percutaneous Coronary Intervention

Author(s) -

Hitinder S. Gurm,

Umesh Tamhane,

Pascal Meier,

Paul Grossman,

Stanley Chetcuti,

Eric Bates

Publication year - 2009

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.108.847996

Subject(s) - abciximab , eptifibatide , medicine , tirofiban , percutaneous coronary intervention , myocardial infarction , cardiology , odds ratio , randomized controlled trial

Current guidelines recommend abciximab as the preferred agent for patients undergoing primary percutaneous coronary intervention, yet small-molecule glycoprotein IIb/IIIa inhibitors are more commonly used in clinical practice. The objective of our meta-analysis was to evaluate for differences in clinical outcome between small-molecule glycoprotein IIb/IIIa inhibitors and abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research